Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: To explore the impact of KRAS, NRAS and BRAF mutations as well as KRAS mutation variants in patients with metastatic colorectal cancer (mCRC) receiving first-line therapy. PATIENTS AND METHODS: A total of 1239 patients from five randomized trials (FIRE-1, FIRE-3, AIOKRK0207, AIOKRK0604, RO91) were included into the analysis. Outcome was evaluated by the Kaplan-Meier method, log-rank tests and Cox models. RESULTS: In 664 tumors, no mutation was detected, 462 tumors were diagnosed with KRAS-, 39 patients with NRAS- and 74 patients with BRAF-mutation. Mutations in KRAS were associated with inferior progression-free survival (PFS) and overall survival (OS) [multivariate hazard ratio (HR) for PFS: 1.20 (1.02-1.42), P = 0.03; multivariate HR for OS: 1.41 (1.17-1.70), P < 0.001]. BRAF mutation was also associated with inferior PFS [multivariate HR: 2.19 (1.59-3.02), P < 0.001] and OS [multivariate HR: 2.99 (2.10-4.25), P < 0.001]. Among specific KRAS mutation variants, the KRAS G12C-variant (n = 28) correlated with inferior OS compared with unmutated tumors [multivariate HR 2.26 (1.25-4.1), P = 0.001]. A similar trend for OS was seen in the KRAS G13D-variant [n = 71, multivariate HR 1.46 (0.96-2.22), P = 0.10]. More frequent KRAS exon 2 variants like G12D [n = 152, multivariate HR 1.17 (0.86-1.6), P = 0.81] and G12V [n = 92, multivariate HR 1.27 (0.87-1.86), P = 0.57] did not have significant impact on OS. CONCLUSION: Mutations in KRAS and BRAF were associated with inferior PFS and OS of mCRC patients compared with patients with non-mutated tumors. KRAS exon 2 mutation variants were associated with heterogeneous outcome compared with unmutated tumors with KRAS G12C and G13D (trend) being associated with rather poor survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Approximately 45% of patients diagnosed with mCRC have KRAS mutations, and the presence of mutations is important both in terms of prognosis [9,10].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [9]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, the KRAS p.G12C mutation is associated with poorer prognosis in terms of progression-free survival (PFS) and overall survival (OS) compared to other KRAS mutations as well as KRAS wild-type tumors.4-7”
From Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A pooled analysis by the Arbeitsgemeinschaft Internistische Onkologie [AIO] study group revealed that KRAS G12C mutation was significantly associated with lower OS compared with tumors with no KRAS mutations [16]”
From The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study (2021) · cites this paper as [16]
In the citing paper
“Patients with other KRASm, including KRAS G12A/D/S/V and KRAS G13D, had OS times ranging from 17.6 to 25.2 months.51”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [51]
In the citing paper
“A post hoc analysis of pooled clinical data from 1239 patients from 5 randomized trials, in which patients with mCRC were treated with chemotherapy with or without bevacizumab as first-line treatment (67%), reported that patients harboring KRAS G12C had the shortest median OS (16.8 [95% CI: 15.6, 18.0] months).51”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [51]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 3×
“Despite the limitation of sample size in single trials, BRAF mutation represents a consistently poor prognostic marker in the context of mCRC treatment [1, 11, 12], associated with rapid clinical deterioration after progression to initial therapy [12].”
BackgroundDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882 · cited 2×
“Despite the limitation of sample size in single trials, BRAF mutation represents a consistently poor prognostic marker in the context of mCRC treatment [1, 11, 12], associated with rapid clinical deterioration after progression to initial therapy [12].”
BackgroundHeinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Self-citationCremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., Mezi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00122-9 · Cited by 1,092 · cited 3×
“well with recent reports of first-line treatment in mCRC [5, 24].”
BackgroundResultVan Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
Self-citationBokemeyer, C., Bondarenko, I., Hartmann, J. T., de Braud, F., Schuch, G., Zubel, A., Celik, I., Schlichting, M., & Koralewski, P. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq632 · Cited by 775
De Roock, W., Jonker, D. J., Di Nicolantonio, F., Sartore-Bianchi, A., Tu, D., Siena, S., Lamba, S., Arena, S., Frattini, M., Piessevaux, H., et al. (2010) · JAMA · doi:10.1001/jama.2010.1535 · Cited by 748
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
Missiaglia, E., Jacobs, B., D'Ario, G., Di Narzo, A. F., Soneson, C., Budinska, E., Popovici, V., Vecchione, L., Gerster, S., Yan, P., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu275 · Cited by 646
Simkens, L. H. J., van Tinteren, H., May, A., ten Tije, A. J., Creemers, G.-J. M., Loosveld, O. J. L., de Jongh, F. E., Erdkamp, F. L. G., Erjavec, Z., van der Torren, A. M. E., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62004-3 · Cited by 517
Corcoran, R. B., Atreya, C. E., Falchook, G. S., Kwak, E. L., Ryan, D. P., Bendell, J. C., Hamid, O., Messersmith, W. A., Daud, A., Kurzrock, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2471 · Cited by 507
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
Yokota, T., Ura, T., Shibata, N., Takahari, D., Shitara, K., Nomura, M., Kondo, C., Mizota, A., Utsunomiya, S., Muro, K., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.19 · Cited by 401
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann, J., Zeindl-Eberhart, E., Kirchner, T., & Jung, A. (2009) · Pathology - Research and Practice · doi:10.1016/j.prp.2009.07.010 · Cited by 361
Self-citationTejpar, S., Celik, I., Schlichting, M., Sartorius, U., Bokemeyer, C., & Van Cutsem, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2592 · Cited by 353
Porschen, R., Arkenau, H.-T., Kubicka, S., Greil, R., Seufferlein, T., Freier, W., Kretzschmar, A., Graeven, U., Grothey, A., Hinke, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2684 · Cited by 280
Self-citationHegewisch-Becker, S., Graeven, U., Lerchenmüller, C. A., Killing, B., Depenbusch, R., Steffens, C.-C., Al-Batran, S.-E., Lange, T., Dietrich, G., Stoehlmacher, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00042-x · Cited by 251 · cited 2×
“patients andmethods studies This analysis is based on individual patient data from five first-line trials in mCRC: FIRE-1 [14, 15], FIRE-3 (only bevacizumab-arm) [2, 16, 17], AIO KRK 0604 [18], AIO KRK 0207 [19] and RO91 [20].”
BackgroundMethodSelf-citationPeeters, M., Douillard, J.-Y., Van Cutsem, E., Siena, S., Zhang, K., Williams, R., & Wiezorek, J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.1492 · Cited by 232
Bazan, V., Migliavacca, M., Zanna, I., Tubiolo, C., Grassi, N., Latteri, M. A., La Farina, M., Albanese, I., Dardanoni, G., Salerno, S., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf226 · Cited by 225
Taieb, J., Zaanan, A., Le Malicot, K., Julié, C., Blons, H., Mineur, L., Bennouna, J., Tabernero, J., Mini, E., Folprecht, G., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5225 · Cited by 154
Stintzing, S., von Weikersthal, L. F., Decker, T. W., Vehling‐Kaiser, U., Jäger, E., Heintges, T., Stoll, C. G., Giessen, C. A., Modest, D. P., Neumann, J. H. L., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr571 · Cited by 114
Self-citationFrequency and Type of KRAS Mutations in Routine Diagnostic Analysis of Metastatic Colorectal Cancer
Neumann, J., Zeindl-Eberhart, E., Kirchner, T., & Jung, A. (2009) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0029-1242277 · Cited by 97
Self-citationSchmiegel, W., Reinacher-Schick, A. C., Arnold, D., Kubicka, S., Freier, W., Dietrich, G., Geißler, M., Hegewisch-Becker, S., Tannapfel, A., Pohl, M., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt028 · Cited by 72
Self-citationvon Weikersthal, L. F., Schalhorn, A., Stauch, M. B., Quietzsch, D., Maubach, P. A., Lambertz, H., Oruzio, D. V., Schlag, R., Weigang-Köhler, K., Vehling-Kaiser, U., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.09.022 · Cited by 58
Self-citationStahler, A., Heinemann, V., Giessen‐Jung, C., Crispin, A., Schalhorn, A., Stintzing, S., von Weikersthal, L. F., Vehling‐Kaiser, U., Stauch, M. B., Quietzsch, D., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29807 · Cited by 38
Self-citationPrognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients
Vincenzi, B., Cremolini, C., Sartore-Bianchi, A., Russo, A., Mannavola, F., Perrone, G., Pantano, F., Loupakis, F., Rossini, D., Ongaro, E., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5231 · Cited by 36
Modest, D. P., Brodowicz, T., Stintzing, S., Jung, A., Neumann, J., Laubender, R. P., Ocvirk, J., Kurteva, G., Papai, Z., Knittelfelder, R., et al. (2012) · Oncology · doi:10.1159/000339534 · Cited by 27
Self-citationReinacher‐Schick, A., Schulmann, K., Modest, D. P., Bruns, N., Graeven, U., Jaworska, M., Greil, R., Porschen, R., Arnold, D., Schmiegel, W., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-349 · Cited by 15
Self-citationČamaj, P., Primo, S., Wang, Y., Heinemann, V., Zhao, Y., Laubender, R. P., Stintzing, S., Gießen-Jung, C., Jung, A., Gamba, S., et al. (2015) · Future Oncology · doi:10.2217/fon.15.97 · Cited by 13
Self-citationSeligmann, J. F., Fisher, D. J., Elliott, F., Richman, S. D., Butler, R., Cheadle, J. P., Adams, R., Quirke, P., Maughan, T., Seymour, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3509 · Cited by 11
Research works printed but not linked: 1
- 19. Stintzing S, Jung A, Rossius L, Modest DP et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3 A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type KRAS (exon 2) metastatic colorectal cancer patients. In ESMO/ECCO, 2013; Abstract E17-7073.
Cited by
Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review
Biller, L. H., & Schrag, D. (2021) · JAMA · doi:10.1001/jama.2021.0106 · Cited by 2,604
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
Arnold, D., Lueza, B., Douillard, J.-Y., Peeters, M., Lenz, H.-J., Venook, A., Heinemann, V., Van Cutsem, E., Pignon, J.-P., Tabernero, J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx175 · Cited by 838
Self-citationTumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Iron Homeostasis and Ferroptosis in Human Diseases: Mechanisms and Therapeutic Prospects
Ru, Q., Li, Y., Chen, L., Wu, Y., Min, J., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01969-z · Cited by 724
Metadata
- Authors
- Modest, D. P., Ricard, I., Heinemann, V., Hegewisch-Becker, S., Schmiegel, W., Porschen, R., Stintzing, S., Graeven, U., Arnold, D., von Weikersthal, L. F., Giessen-Jung, C., Stahler, A., Schmoll, H. J., Jung, A., Kirchner, T., Tannapfel, A., & Reinacher-Schick, A.
- Affiliations
- German Cancer Research Center (DE)
- Ludwig-Maximilians-Universität München (DE)
- Universitätsklinikum Knappschaftskrankenhaus Bochum (DE)
- Kliniken Maria Hilf (DE)
- LMU Klinikum (DE)
- University Hospital in Halle (DE)
- Ruhr University Bochum (DE)
- Corresponding author
- Modest, D.P.
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 27
- Issue
- 9
- Pages
- 1746-1753
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC4999563
- OpenAlex
- W2465450966
- Semantic Scholar
- c6c03496c35c248a5905726558f97863fff59b9b
- Cited by
- 351
- References
- 31
- Citations by year
- 2026: 25 · 2025: 48 · 2024: 63 · 2023: 50 · 2022: 33 · 2021: 39 · 2020: 40 · 2019: 20 · 2018: 15 · 2017: 15 · 2016: 2
- FWCI
- 9.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc/4.0/ (vor, 1160 d)
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- metastatic colorectal cancer, KRAS mutation, NRAS mutation, BRAF mutation, KRAS G12C, KRAS G13D, first-line therapy, progression-free survival, overall survival, predictive biomarkers, prognostic factors
- MeSH terms
- Female, Humans, Male, Membrane Proteins, Mutation, Neoplasm Metastasis, Colorectal Neoplasms, Randomized Controlled Trials as Topic, Proto-Oncogene Proteins p21(ras), Treatment Outcome, Disease-Free Survival, GTP Phosphohydrolases, Proto-Oncogene Proteins B-raf, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.